Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
10:15:41 EDT Mon 29 Apr 2024
Enter Symbol
or Name
USA
CA



Q:KALV - KALVISTA PHARMACEUTICALS INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
KALV - Q0.310.88·10.980.210.88+0.100.95.6579610.92  11.14  10.8816.88  7.2109:57:12Apr 2215 min RT 2¢

Recent Trades - Last 10 of 96
Time ETExPriceChangeVolume
09:57:12Q10.930.156
09:56:58Q10.92560.14561
09:56:34Q10.92830.14835
09:56:24Q10.92280.14285
09:55:58Q10.930.1516
09:55:27Q10.89970.11975
09:55:07Q10.930.1513
09:55:07Q10.920.1414
09:55:07Q10.940.1674
09:55:07Q10.880.1062

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-22 06:30U:KALVNews ReleaseKalVista Pharmaceuticals Appoints William C. Fairey to Board of Directors
2024-04-03 06:30U:KALVNews ReleaseKalVista Pharmaceuticals to Present at 23rd Annual Needham Virtual Healthcare Conference
2024-04-02 06:30U:KALVNews ReleaseKalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-03-18 06:30U:KALVNews ReleaseKalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas
2024-03-12 06:30U:KALVNews ReleaseKalVista Pharmaceuticals Awarded UK Promising Innovative Medicine (PIM) Designation for Sebetralstat
2024-03-11 06:30U:KALVNews ReleaseKalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update
2024-03-08 06:30U:KALVNews ReleaseKalVista Pharmaceuticals to Present HAE Attack Journey Data at 2024 HAEi Regional Conference Americas
2024-03-07 06:30U:KALVNews ReleaseKalVista Pharmaceuticals Announces Appointment of Benjamin L. Palleiko as Chief Executive Officer
2024-03-06 06:30U:KALVNews ReleaseKalVista Pharmaceuticals to Participate in the Leerink Partners 2024 Global Biopharma Conference
2024-03-04 06:30U:KALVNews ReleaseKalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-02-27 06:30U:KALVNews ReleaseKalVista Pharmaceuticals Presents Data on Unmet Needs in HAE from a Patient Perspective at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting
2024-02-26 06:30U:KALVNews ReleaseKalVista Pharmaceuticals Presents Additional Phase 3 KONFIDENT Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting
2024-02-20 06:30U:KALVNews ReleaseKalVista Pharmaceuticals Awarded UK Innovation Passport for Sebetralstat
2024-02-16 06:30U:KALVNews ReleaseKalVista Pharmaceuticals to Present Phase 3 Sebetralstat Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting
2024-02-15 06:30U:KALVNews ReleaseKalVista Pharmaceuticals Announces Pricing of a $160.1 Million Public Offering of Common Stock and Pre-Funded Warrants
2024-02-14 16:18U:KALVNews ReleaseKalVista Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
2024-02-13 06:30U:KALVNews ReleaseKalVista Pharmaceuticals Reports Phase 3 KONFIDENT Trial Meets All Endpoints for Sebetralstat as First Oral On-demand Therapy for Hereditary Angioedema
2024-02-02 06:30U:KALVNews ReleaseKalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-12-20 06:30U:KALVNews ReleaseKalVista Pharmaceuticals Announces Publication of First Oral Factor XIIa Data in Frontiers in Pharmacology
2023-12-07 06:30U:KALVNews ReleaseKalVista Pharmaceuticals Reports Second Fiscal Quarter Results and Provides Operational Update